Rallybio Corp
NASDAQ:RLYB
Intrinsic Value
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. [ Read More ]
The intrinsic value of one RLYB stock under the Base Case scenario is 2.91 USD. Compared to the current market price of 1.63 USD, Rallybio Corp is Undervalued by 44%.
Valuation Backtest
Rallybio Corp
Run backtest to discover the historical profit from buying and selling RLYB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Rallybio Corp
Current Assets | 114.8m |
Cash & Short-Term Investments | 109.9m |
Other Current Assets | 4.9m |
Non-Current Assets | 831k |
Long-Term Investments | 239k |
PP&E | 592k |
Current Liabilities | 9.3m |
Accounts Payable | 976k |
Accrued Liabilities | 8.3m |
Non-Current Liabilities | 173k |
Other Non-Current Liabilities | 173k |
Earnings Waterfall
Rallybio Corp
Revenue
|
0
USD
|
Operating Expenses
|
-78.9m
USD
|
Operating Income
|
-78.9m
USD
|
Other Expenses
|
4.4m
USD
|
Net Income
|
-74.6m
USD
|
Free Cash Flow Analysis
Rallybio Corp
RLYB Profitability Score
Profitability Due Diligence
Rallybio Corp's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Rallybio Corp's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
RLYB Solvency Score
Solvency Due Diligence
Rallybio Corp's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Rallybio Corp's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RLYB Price Targets Summary
Rallybio Corp
According to Wall Street analysts, the average 1-year price target for RLYB is 12.6 USD .
Ownership
RLYB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RLYB Price
Rallybio Corp
Average Annual Return | -33.38% |
Standard Deviation of Annual Returns | 9.89% |
Max Drawdown | -95% |
Market Capitalization | 61.7m USD |
Shares Outstanding | 37 812 000 |
Percentage of Shares Shorted | 4.12% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 35 full-time employees. The company went IPO on 2021-07-29. The firm is engaged in discovering, developing, manufacturing and delivering therapies that improve the lives of patients suffering from severe and rare diseases. The company offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. The company provides RLYB211, a polyclonal anti-HPA-1a antibody. Its RLYB211 is in Phase I/II clinical trial. The Company’s lead product candidate, RLYB212, is a monoclonal anti-HPA-1a antibody. The company is also focused on developing therapies that address diseases of complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and ophthalmic disorders. Its RLYB116 is a long-acting, subcutaneously administered inhibitor of complement factor 5 (C5) in development for the treatment of patients with PNH and gMG. The company also includes RLYB114, which is a pegylated C5 inhibitor.
Contact
IPO
Employees
Officers
The intrinsic value of one RLYB stock under the Base Case scenario is 2.91 USD.
Compared to the current market price of 1.63 USD, Rallybio Corp is Undervalued by 44%.